Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shionogi Pharma Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action represents the entirety of the company's current pending workload as tracked in this profile. The prosecution is concentrated within 1 distinct art unit, which suggests a specific technological focus for the company's recent patenting activity in this sector.
The examination process involves 1 distinct examiner, ensuring that the current pending matter is not divided among multiple points of contact at the patent office. This one-to-one relationship between pending actions and examiners simplifies the administrative oversight required for the portfolio. Practitioners can focus their strategy on the specific requirements and tendencies of this single individual.
CARCANAGUE, DANIEL R is identified as the busiest examiner for Shionogi Pharma Co. Ltd., currently overseeing 1 pending office action. Because this examiner is responsible for the only pending action in the portfolio, their individual examination style will be the primary factor in the company's immediate prosecution outcomes. The presence of 1 busiest examiner pending further confirms the highly focused nature of the current docket.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CARCANAGUE, DANIEL R | 1 | 80.8% | +24.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18196255 | NOVEL ACRIDINIUM SALT AND METHOD FOR PRODUCING SAME | CARCANAGUE, DANIEL R | 83d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18196255 | NOVEL ACRIDINIUM SALT AND METHOD FOR PRODUCING SAME | CARCANAGUE, DANIEL R | 83d |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18196255 | NOVEL ACRIDINIUM SALT AND METHOD FOR PRODUCING SAME | CARCANAGUE, DANIEL R | 1621 | §103§112 | Non-Final OA | 83d | Pending | May 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial